Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00881556 · ClinicalTrials.gov registry record · Early Phase 1
Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB)
A Early Phase 1 study, sponsored by Columbia University.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 3
- Enrollment target
NCT00881556 is a Early Phase 1 study that was terminated before completion, run by Columbia University. The registered enrollment target is 3 participants.
The verdict
NCT00881556, a Early Phase 1 study, was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
Reduced Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (AlloSCT) from family-related donors and unrelated cord blood (UCB) donors will be safe and well tolerated in selected patients with RDEB. To determine the event-free survival (EFS) and overall survival (OS) following RIC consisting of busulfan/fludarabine/alemtuzumab (BFA) and AlloSCT in selected patients with RDEB.
Interventions
- DRUG Fludarabine
- DRUG Busulfan
- DRUG Alemtuzumab
- DRUG Palifermin
- DRUG Lorazepam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2009-08-20 |
| Est. Completion | 2015-09 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00881556
The ClinicalTrials.gov registry entry for NCT00881556 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Fludarabine is the first listed.
NCT00881556 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00881556 about?
NCT00881556 is a clinical study titled "Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB)". Reduced Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (AlloSCT) from family-related donors and unrelated cord blood (UCB) donors will be safe and well tolerated in selected patients with RDEB. To determine the event-free survival (EFS) and overall survival (OS) following RIC...
What is the current status of trial NCT00881556?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 3 participants. The study started on 2009-08-20. Estimated completion is 2015-09.
What interventions are being tested in trial NCT00881556?
The interventions under investigation include: Fludarabine (DRUG), Busulfan (DRUG), Alemtuzumab (DRUG), Palifermin (DRUG), Lorazepam (DRUG).
Who is sponsoring clinical trial NCT00881556?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.